These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 9398054)

  • 21. Irinophore C™, a lipid nanoparticulate formulation of irinotecan, improves vascular function, increases the delivery of sequentially administered 5-FU in HT-29 tumors, and controls tumor growth in patient derived xenografts of colon cancer.
    Neijzen R; Wong MQ; Gill N; Wang H; Karim T; Anantha M; Strutt D; Waterhouse D; Bally MB; Tai IT; Ng SS; Yapp DT
    J Control Release; 2015 Feb; 199():72-83. PubMed ID: 25497312
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer: role of drug sequence and dose.
    Cao S; Rustum YM
    Cancer Res; 2000 Jul; 60(14):3717-21. PubMed ID: 10919639
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sequence-dependent growth inhibition and DNA damage formation by the irinotecan-5-fluorouracil combination in human colon carcinoma cell lines.
    Mans DR; Grivicich I; Peters GJ; Schwartsmann G
    Eur J Cancer; 1999 Dec; 35(13):1851-61. PubMed ID: 10674003
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Schedule-dependent efficacy of camptothecins in models of human cancer.
    Houghton PJ; Stewart CF; Zamboni WC; Thompson J; Luo X; Danks MK; Houghton JA
    Ann N Y Acad Sci; 1996 Dec; 803():188-201. PubMed ID: 8993512
    [No Abstract]   [Full Text] [Related]  

  • 25. Inhibitory effect of combined administration with CPT-11 and 5-fluorouracil in vitro and in vivo.
    Satoh H; Ohtomo M; Ishikawa H; Kamma H; Ohtsuka M; Hasegawa S
    Cancer Biochem Biophys; 1999 Jul; 17(1-2):59-67. PubMed ID: 10738902
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Irinotecan-induced cytotoxicity to colon cancer cells in vitro is stimulated by pre-incubation with trifluorothymidine.
    Temmink OH; Hoebe EK; Fukushima M; Peters GJ
    Eur J Cancer; 2007 Jan; 43(1):175-83. PubMed ID: 17049227
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antitumor activity of new combination chemotherapy with irinotecan hydrochloride and nedaplatin against human cervical cancer cell lines.
    Yamamoto K; Iwahana M; Kumazawa E; Kakihata K; Abe K; Hirano F; Tohgo A; Hoshiai H; Noda K
    Oncol Rep; 2003; 10(3):593-8. PubMed ID: 12684629
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A predictive pharmacokinetic-pharmacodynamic model of tumor growth kinetics in xenograft mice after administration of anticancer agents given in combination.
    Terranova N; Germani M; Del Bene F; Magni P
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):471-82. PubMed ID: 23812004
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemotherapy for colorectal cancer.
    Goyle S; Maraveyas A
    Dig Surg; 2005; 22(6):401-14. PubMed ID: 16479107
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human HT-29 colon carcinoma and human CaKi1 renal cell carcinoma xenografts.
    Teicher BA; Menon K; Alvarez E; Galbreath E; Shih C; Faul MM
    Anticancer Res; 2001; 21(5):3175-84. PubMed ID: 11848470
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The synergistic effects of low-dose irinotecan and TRAIL on TRAIL-resistant HT-29 colon carcinoma in vitro and in vivo.
    Zhu H; Zhao F; Yu S; He J; Deng L; Yi C; Huang Y
    Int J Mol Med; 2012 Nov; 30(5):1087-94. PubMed ID: 22922573
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of protein kinase C in the synergistic interaction of safingol and irinotecan in colon cancer cells.
    Ling LU; Lin H; Tan KB; Chiu GN
    Int J Oncol; 2009 Dec; 35(6):1463-71. PubMed ID: 19885570
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors.
    Houghton PJ; Cheshire PJ; Hallman JD; Lutz L; Friedman HS; Danks MK; Houghton JA
    Cancer Chemother Pharmacol; 1995; 36(5):393-403. PubMed ID: 7634381
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Optimal dosing schedule in combination therapy with irinotecan and doxifluridine in a human colorectal cancer xenograft model].
    Yanagisawa M; Ishikawa T; Ouchi KF; Tanaka Y
    Gan To Kagaku Ryoho; 2003 Feb; 30(2):223-30. PubMed ID: 12610870
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts.
    Azrak RG; Cao S; Slocum HK; Tóth K; Durrani FA; Yin MB; Pendyala L; Zhang W; McLeod HL; Rustum YM
    Clin Cancer Res; 2004 Feb; 10(3):1121-9. PubMed ID: 14871992
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice.
    Allegrini G; Goulette FA; Darnowski JW; Calabresi P
    Cancer Chemother Pharmacol; 2004 Mar; 53(3):261-6. PubMed ID: 14658007
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevention of intestinal toxic effects and intensification of irinotecan's therapeutic efficacy against murine colon cancer liver metastases by oral administration of the lipopeptide JBT 3002.
    Shinohara H; Killion JJ; Kuniyasu H; Kumar R; Fidler IJ
    Clin Cancer Res; 1998 Sep; 4(9):2053-63. PubMed ID: 9748119
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synergism between 5-fluorouracil and N-methylformamide in HT29 human colon cancer line.
    Laudonio N; Zupi G; Erba E; Leonetti C; D'Incalci M
    Br J Cancer; 1990 Mar; 61(3):377-81. PubMed ID: 2328201
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL.
    Ravi R; Jain AJ; Schulick RD; Pham V; Prouser TS; Allen H; Mayer EG; Yu H; Pardoll DM; Ashkenazi A; Bedi A
    Cancer Res; 2004 Dec; 64(24):9105-14. PubMed ID: 15604280
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: In vivo activity and mechanisms.
    Wang H; Wang S; Nan L; Yu D; Agrawal S; Zhang R
    Int J Oncol; 2002 Apr; 20(4):745-52. PubMed ID: 11894120
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.